Mucosis B.V. and PATH sign agree­ment to pur­sue Mimopath™-based oral diar­rhea vac­cines

Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. announced today that it has entered into a col­lab­o­ra­tion agree­ment with the glob­al health non­prof­it orga­ni­za­tion PATH to pur­sue the use of the company’s Mimopath™ tech­nol­o­gy in oral vac­cines to pre­vent and treat severe diar­rhea.

Severe dehy­drat­ing diar­rhea is the sec­ond lead­ing cause of death in chil­dren in devel­op­ing coun­tries and fre­quent­ly caus­es dis­ease in trav­el­ers vis­it­ing those areas. Shigella and entero­tox­i­genic E. coli (ETEC) are the lead­ing bac­te­r­i­al caus­es of diar­rhea. Currently, no vac­cines against those bac­te­ria exist. PATH sup­ports the devel­op­ment of Shigella and ETEC vac­cines.

Because Mimopath™-based vac­cines have the poten­tial to raise a strong immune response in the gut after oral admin­is­tra­tion, PATH is sup­port­ing Mucosis to estab­lish proof of con­cept in ani­mals. PATH will cov­er the company’s research costs up to US$600,000. If proof of con­cept is gen­er­at­ed, the col­lab­o­ra­tion may be expand­ed.

“We are very proud to col­lab­o­rate with PATH in apply­ing our tech­nol­o­gy to the vital task of find­ing new vac­cines tar­get­ing the threat of Shigella and ETEC,” said Govert Schouten, CEO of Mucosis.

Mucosis already col­lab­o­rates with PATH on intranasal pneu­mo­coc­cal vac­cines based on Mimopath™. This pro­gram start­ed in 2009.

Leave a Reply

Your email address will not be published. Required fields are marked *